EUVIMEDTutustu EUVIMEDiin
ValidierungsstudieOpen access · CC BY-NC-ND 4.0

Validation of daily 0.35 T diffusion‐weighted MRI for MRI‐guided glioblastoma radiotherapy

Natalia Lutsik, Siamak P Nejad-Davarani, Alessandro Valderrama, Janette Herr, Danilo Maziero, Kaylie Cullison, Gregory A Azzam, Gregory J Kubicek, Jessica Meshman, Macarena I de la Fuente, Tess Armstrong, Eric A Mellon

Medical Physics · 2024

DOI: 10.1002/mp.17067 ↗

At a glance

Validierungsstudie in Medical Physics, 2024. Written by Natalia Lutsik and 11 co-authors. Institution: Department of Radiation Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA. Major MEDLINE topics: Glioblastoma, Diffusion Magnetic Resonance Imaging, Radiotherapy, Image-Guided, Phantoms, Imaging. Cited 9 times so far (Crossref); 25 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NCI NIH HHS, National Cancer Institute of the National Institutes of Health.

TiivistelmäSubjectsBibliografiset tiedotCiteRelated studies

Abstract (original language)

Background

MRI‐Linac systems enable daily diffusion‐weighed imaging (DWI) MRI scans for assessing glioblastoma tumor changes with radiotherapy treatment.

Purpose

Our study assessed the image quality of echoplanar imaging (EPI)‐DWI scans compared with turbo spin echo (TSE)‐DWI scans at 0.35 Tesla (T) and compared the apparent diffusion coefficient (ADC) values and distortion of EPI‐DWI on 0.35 T MRI‐Linac compared to high‐field diagnostic MRI scanners.

Methods

The calibrated National Institute of Standards and Technology (NIST)/Quantitative Imaging Biomarkers Alliance (QIBA) Diffusion Phantom was scanned on a 0.35 T MRI‐Linac, and 1.5 T and 3 T MRI with EPI‐DWI. Five patients were scanned on a 0.35 T MRI‐Linac with a TSE‐DWI sequence, and five other patients were scanned with EPI‐DWI on a 0.35 T MRI‐Linac and a 3 T MRI. The quality of images was compared between the TSE‐DWI and EPI‐DWI on the 0.35 T MRI‐Linac assessing signal‐to‐noise ratios and presence of artifacts. EPI‐DWI ADC values and distortion magnitude were measured and compared between 0.35 T MRI‐Linac and high‐field MRI for both phantom and patient studies.

Results

The average ADC differences between EPI‐DWI acquired on the 0.35 T MRI‐Linac, 1.5 T and 3 T MRI scanners and published references in the phantom study were 1.7%, 0.4% and 1.0%, respectively. Comparing the ADC values based on EPI‐DWI in glioblastoma tumors, there was a 3.36% difference between 0.35 and 3 T measurements. Susceptibility‐induced distortions in the EPI‐DWI phantoms were 0.46 ± 1.51 mm for 0.35 MRI‐Linac, 0.98 ± 0.51 mm for 1.5 T MRI and 1.14 ± 1.88 mm for 3 T MRI; for patients ‐0.47 ± 0.78 mm for 0.35 T and 1.73 ± 2.11 mm for 3 T MRIs. The mean deformable registration distortion for a phantom was 1.1 ± 0.22 mm, 3.5 ± 0.39 mm and 4.7 ± 0.37 mm for the 0.35 T MRI‐Linac, 1.5 T MRI, and 3 T MRI scanners, respectively; for patients this distortion was –0.46 ± 0.57 mm for 0.35 T and 4.2 ± 0.41 mm for 3 T. EPI‐DWI 0.35 T MRI‐Linac images showed higher SNR and lack of artifacts compared with TSE‐DWI, especially at higher b ‐values up to 1000 s/mm 2 .

Conclusion

EPI‐DWI on a 0.35 T MRI‐Linac showed superior image quality compared with TSE‐DWI, minor and less distortions than high‐field diagnostic scanners, and comparable ADC values in phantoms and glioblastoma tumors. EPI‐DWI should be investigated on the 0.35 T MRI‐Linac for prediction of early response in patients with glioblastoma.

Subjects

MeSH terms (MEDLINE)

GlioblastomaDiffusion Magnetic Resonance ImagingRadiotherapy, Image-GuidedPhantoms, ImagingHumansBrain NeoplasmsSignal-To-Noise RatioImage Processing, Computer-Assisted

Author keywords

MRI‐Linacdiffusion‐weighted MRIglioblastoma

Authors and institutions

  • Department of Radiation Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA.
  • Department of Radiation Medicine & Applied Sciences, UC San Diego Health, La Jolla, California, USA.
  • Neuro-Oncology division, University of Miami Miller School of Medicine, Miami, Florida, USA.
  • Former ViewRay, Inc., Ohio, USA.

Funding

  • NCI NIH HHS
  • National Cancer Institute of the National Institutes of Health

Cite

APA

Lutsik, N., Nejad-Davarani, S. P., Valderrama, A., Herr, J., Maziero, D., Cullison, K., Azzam, G. A., Kubicek, G. J., Meshman, J., de la Fuente, M. I., Armstrong, T., & Mellon, E. A. (2024). Validation of daily 0.35 T diffusion‐weighted MRI for MRI‐guided glioblastoma radiotherapy. Medical Physics. https://doi.org/10.1002/mp.17067

Vancouver

Lutsik N, Nejad-Davarani SP, Valderrama A, Herr J, Maziero D, Cullison K, et al. Validation of daily 0.35 T diffusion‐weighted MRI for MRI‐guided glioblastoma radiotherapy. Medical Physics. 2024. doi:10.1002/mp.17067

BibTeX
@article{Lutsik2024,
  author = {Lutsik, Natalia and Nejad-Davarani, Siamak P and Valderrama, Alessandro and Herr, Janette and Maziero, Danilo and Cullison, Kaylie and Azzam, Gregory A and Kubicek, Gregory J and Meshman, Jessica and de la Fuente, Macarena I and Armstrong, Tess and Mellon, Eric A},
  title = {Validation of daily 0.35 T diffusion‐weighted MRI for MRI‐guided glioblastoma radiotherapy},
  journal = {Medical Physics},
  year = {2024},
  doi = {10.1002/mp.17067}
}
Start for free →